Anxiety Disorder Treatment Market Size Projection, Future Outlook, Business Overview, Latest Trends and Top Key Players By 2025
newyorktelegraph.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from newyorktelegraph.com Daily Mail and Mail on Sunday newspapers.
Cognoptix Announces Formation of a New Board of Directors
News provided by
Share this article
Share this article
MARLBOROUGH, Mass., Dec. 30, 2020 /PRNewswire/ Cognoptix is a breakthrough diagnostics company developing an innovative office-based device-drug system for the early detection of Alzheimer s disease (AD). As another milestone of the Series R restart, recapitalization, and revitalization, the company named a new Board of Directors (BOD) formed under the leadership of Dr. Susanne Wilke, Ph.D., Cognoptix new President and CEO.
In addition to Dr. Wilke, the five-member board includes Dr. Lee E. Goldstein, Cognoptix co-founder and co-chair of the company s Scientific Advisory Board (SAB); R. Gregg Stone and John Conley, both are members of the Launchpad Venture Group which led the Cognoptix Series R fundraising and is a nationally recognized leader among angel networks; and H. Lawrence Remmel, Esq., Partner and Chair of the Banking and Finance Group at Pryor Cashman.
Pain management devices market 2020 Global Trends, Emerging Technologies And Growth Analysis By Forecast To 2023
Questo comunicato è stato pubblicato più di 3 mesi fa. Le informazioni su questa pagina potrebbero non essere attendibili. Pain Management Market Growing Demand, Scope and Trend By Devices (Neurostimulation, Ablation Devices, Others), Drugs (NSAIDS, Anticonvulsants, Opioids, Others), Indication (Neuropathic Pain, Fibromyalgia, Others), Mode of Purchase, End-User – Global Forecast Till 2023 Pain Management Market According to the new report published by Market Research Future, the global pain management market is on the verge of gaining high traction at a CAGR of 6.0% during the forecast period 2018-2023. Top Eminent Key Players
Almirall, S.A. (ALM.MC) and Forest Laboratories, Inc. announced that the U.S. Food and Drug Administration (FDA) has approved Tudorza(TM) Pressair(TM) (aclidinium bromide inhalation powder) for the long-term maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema. COPD is a common, progressive, and debilitating lung disease characterized by persistent airflow limitation that makes it hard to breathe; it is currently the third leading cause of mortality in the US. Characteristic symptoms include breathlessness, excessive production of sputum, and a chronic cough. Tudorza(TM) is a twice-daily inhaled long-acting anticholinergic, also referred to as a long-acting muscarinic antagonist (LAMA). Tudorza(TM) produces bronchodilation by inhibiting acetylcholine s effect on muscarinic receptors in the airway smooth muscle. Forest expects Tudorza(TM) Pressair(TM) to be available to wholesalers in the
vimarsana © 2020. All Rights Reserved.